Choueiri TK, Larkin JMG, Oya M, et al. First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. J Clin Oncol. 2017;35 (suppl; abstr 4504).
Zorginstituut adviseert over toelating pembrolizumab (Keytruda) bij TNBC
mei 2024 | Borstkanker